Bexmarilimab Biosimilar – Anti-STAB1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1817; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Bexmarilimab Biosimilar, also known as Anti-STAB1 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Bexmarilimab therapeutic antibody. This biosimilar has been designed to specifically target STAB1, a protein that has been implicated in various diseases and disorders. In this article, we will explore the structure, activity, and potential applications of Bexmarilimab Biosimilar in research.
Bexmarilimab Biosimilar is a monoclonal antibody, which means it is a type of protein that is produced by immune cells in a laboratory setting. The structure of Bexmarilimab Biosimilar is similar to that of the original Bexmarilimab antibody, with minor differences in the amino acid sequence. This biosimilar is composed of two identical heavy chains and two identical light chains, held together by disulfide bonds. The heavy and light chains are further divided into constant and variable regions, with the variable regions being responsible for the antibody’s specificity towards STAB1.
Bexmarilimab Biosimilar has been specifically designed to target STAB1, a protein that has been found to play a role in various diseases and disorders. STAB1, also known as stabilin-1, is a transmembrane protein that is expressed on the surface of cells. It is involved in various cellular processes, including cell adhesion, migration, and clearance of waste products. However, dysregulation of STAB1 has been linked to several diseases, such as cancer, inflammation, and fibrosis. Bexmarilimab Biosimilar works by binding to STAB1 and inhibiting its activity, thus potentially preventing or treating these diseases.
As a biosimilar to Bexmarilimab, this antibody has the potential to be used in various research applications. Some of the potential applications of Bexmarilimab Biosimilar in research include:
1.
Cancer Research: STAB1 has been found to be overexpressed in various types of cancer, such as breast, lung, and colon cancer. Bexmarilimab Biosimilar could potentially be used in cancer research to study the role of STAB1 in tumor growth and progression. It could also be used as a therapeutic agent to target STAB1 and inhibit its activity, thus potentially slowing down or stopping the growth of cancer cells.
2. Inflammation Research: STAB1 has been implicated in various inflammatory diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Bexmarilimab Biosimilar could be used in research to study the role of STAB1 in these diseases and potentially develop new treatments targeting this protein.
3. Fibrosis Research: STAB1 has been found to be involved in the development of fibrosis, a condition where excessive scar tissue forms in organs, impairing their function. Bexmarilimab Biosimilar could be used in research to study the role of STAB1 in fibrosis and potentially develop new treatments to prevent or reverse this condition.
4. Drug Development: Bexmarilimab Biosimilar could also be used in research to develop new drugs targeting STAB1. By understanding the structure and activity of this biosimilar, researchers could potentially modify it to enhance its therapeutic properties and develop more effective treatments for diseases involving STAB1.
In summary, Bexmarilimab Biosimilar is a monoclonal antibody that has been designed as a biosimilar to the original Bexmarilimab therapeutic antibody. Its structure is similar to that of the original antibody, with minor differences in the amino acid sequence. Bexmarilimab Biosimilar specifically targets STAB1, a protein involved in various diseases and disorders. Its potential applications in research include cancer, inflammation, and fibrosis research, as well as drug development. Further studies and research on this biosimilar could potentially lead to the development of new and
ProteoGenix catalogue number PX-TA1817. For research use only.
Target: Bexmarilimab Biosimilar – Anti-STAB1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Bexmarilimab Biosimilar – Anti-STAB1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
